Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers.

Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, Weers JG.

Chest. 2003 Jul;124(1):360-6.

PMID:
12853545
2.

Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs.

Newman SP, Pitcairn GR, Hirst PH, Rankin L.

Adv Drug Deliv Rev. 2003 Jul 18;55(7):851-67. Review.

PMID:
12842604
3.

New developments in radionuclide imaging for assessing drug delivery in man.

Newman SP, Hirst PH, Wilding IR.

Eur J Pharm Sci. 2003 Jan;18(1):19-22. No abstract available.

PMID:
12554068
4.

Deposition and pharmacokinetics of budesonide from the Miat Monodose inhaler, a simple dry powder device.

Ball DJ, Hirst PH, Newman SP, Sonet B, Streel B, Vanderbist F.

Int J Pharm. 2002 Oct 1;245(1-2):123-32.

PMID:
12270249
5.

Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder.

Duddu SP, Sisk SA, Walter YH, Tarara TE, Trimble KR, Clark AR, Eldon MA, Elton RC, Pickford M, Hirst PH, Newman SP, Weers JG.

Pharm Res. 2002 May;19(5):689-95.

PMID:
12069174
6.

In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler.

Hirst PH, Pitcairn GR, Weers JG, Tarara TE, Clark AR, Dellamary LA, Hall G, Shorr J, Newman SP.

Pharm Res. 2002 Mar;19(3):258-64.

PMID:
11934231
7.

Deposition and pharmacokinetics of an HFA formulation of triamcinolone acetonide delivered by pressurized metered dose inhaler.

Hirst PH, Pitcairn GR, Richards JC, Rohatagi S, Gillen MS, Newman SP.

J Aerosol Med. 2001 Summer;14(2):155-65.

PMID:
11681648
8.

A brief history of gamma scintigraphy.

Newman SP, Pitcairn GR, Hirst PH.

J Aerosol Med. 2001 Summer;14(2):139-45.

PMID:
11681646
9.

A comparison of the lung deposition of budesonide from Easyhaler, Turbuhaler and pMDI plus spacer in asthmatic patients.

Hirst PH, Bacon RE, Pitcairn GR, Silvasti M, Newman SP.

Respir Med. 2001 Sep;95(9):720-7.

10.

Scintigraphic evaluation of lung deposition with a novel inhaler device.

Newman SP, Hirst PH, Pitcairn GR.

Curr Opin Pulm Med. 2001 Apr;7 Suppl 1:S12-4.

PMID:
11385810
11.

Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler.

Pickering H, Pitcairn GR, Hirst PH, Bacon PR, Newman SP, Affrime MB, Marino M.

Clin Ther. 2000 Dec;22(12):1483-93.

PMID:
11192139
12.

Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products?

Newman SP, Wilding IR, Hirst PH.

Int J Pharm. 2000 Nov 4;208(1-2):49-60. Review.

PMID:
11064211
13.

Scintigraphic comparison of budesonide deposition from two dry powder inhalers.

Newman SP, Pitcairn GR, Hirst PH, Bacon RE, O'Keefe E, Reiners M, Hermann R.

Eur Respir J. 2000 Jul;16(1):178-83.

14.

Inositol polyphosphate-mediated iron transport in Pseudomonas aeruginosa.

Hirst PH, Riley AM, Mills SJ, Spiers ID, Poyner DR, Freeman S, Potter BV, Smith AW.

J Appl Microbiol. 1999 Mar;86(3):537-43.

15.

Synthesis and iron binding studies of myo-inositol 1,2,3-trisphosphate and (+/-)-myo-inositol 1,2-bisphosphate, and iron binding studies of all myo-inositol tetrakisphosphates.

Spiers ID, Barker CJ, Chung SK, Chang YT, Freeman S, Gardiner JM, Hirst PH, Lambert PA, Michell RH, Poyner DR, Schwalbe CH, Smith AW, Solomons KR.

Carbohydr Res. 1996 Feb 28;282(1):81-99.

PMID:
8721738
16.

The pyocin Sa receptor of Pseudomonas aeruginosa is associated with ferripyoverdin uptake.

Smith AW, Hirst PH, Hughes K, Gensberg K, Govan JR.

J Bacteriol. 1992 Jul;174(14):4847-9.

Supplemental Content

Loading ...
Support Center